Treating Hairy Cell Leukemia

Hairy cell leukemia (HCL) tends to be slow growing. Patients without symptoms often don't need to be treated right away, but they do need to be watched carefully. Doctor visits are done every few months to check for signs that the HCL is growing and to see if it's causing any problems (like low blood counts, fatigue, or an enlarged spleen). Some people with HCL live for many years without having symptoms or getting treatment.

Treatment may be advised for HCL patients with low blood cell counts, recurrent infections, or an enlarged spleen or lymph nodes. Treatment is most often with chemo using one of the purine analog drugs -- either cladribine (2-CdA) or pentostatin. Most patients get a good response with these drugs, and the responses often last more than 5 years.

If the leukemia comes back, it will most be often treated with a purine analog again. Often the same drug will be used as was given the first time, especially if the HCL stayed in remission for a long time. Sometimes the monoclonal antibody rituximab (Rituxan®) is given along with chemo.

In rare cases, HCL may not respond to chemo. Rituximab or interferon-alfa, a type of biologic therapy, may be helpful.

Another option if other treatments have already been tried is the monoclonal antibody moxetumomab pasudotox (Lumoxiti).

If a patient is uncomfortable because of an enlarged spleen, surgery to remove the spleen (splenectomy) can often help relieve pain.

Like chronic lymphocytic leukemia, HCL can cause problems with low blood counts and infections. Treatment of these problems is discussed in Supportive Care in Chronic Lymphocytic Leukemia.

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

National Cancer Institute. Hairy Cell Leukemia Treatment (PDQ®)–Patient Version. April 6, 2016. Accessed at on April 17, 2018.

National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Hairy Cell Leukemia Lymphoma, Version 2.2018 -- September 26, 2017. Accessed at on April 17, 2018.

Last Revised: September 14, 2018

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.